Literature DB >> 17846288

Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass.

Mias Pretorius1, Brian S Donahue, Chang Yu, James P Greelish, Dan M Roden, Nancy J Brown.   

Abstract

BACKGROUND: Postoperative atrial fibrillation (AF), leading to significant morbidity and prolongation of hospital stay, complicates 20% to 40% of surgical procedures requiring cardiopulmonary bypass (CPB). This study tests the hypothesis that biomarkers predict the development of postoperative AF. METHODS AND
RESULTS: We enrolled 253 adult patients undergoing elective cardiac surgery requiring CPB and who were in sinus rhythm at the time of surgery. Blood samples were obtained for measurement of 21 biomarkers immediately after separation from CPB and administration of protamine. Patients who developed postoperative AF (67 subjects, 26.5%) were significantly older (P<0.001), more likely to have a remote history of AF (P<0.001), and tended to be more likely to have had valve surgery (P=0.082). Plasminogen activator inhibitor-1 (P=0.014), interleukin (IL)-6 (P=0.019), and N-terminal prohormone brain natriuretic peptide (P=0.028) concentrations were significantly higher in the blood of patients who developed postoperative AF. Logistic regression identified age (P<0.001), remote history of AF (P=0.001), and postoperative PAI-1 (P=0.036) as independent predictors of postoperative AF. When preoperative PAI-1 antigen concentrations were included in the model age (P<0.001), remote history of AF (P<0.001) and preoperative PAI-1 (P=0.015) were identified as independent predictors of postoperative AF. The Chi-squared Automatic Interaction Detection (CHAID) model indicated that age was the primary determinant for the development of postoperative AF (17% in age < or = 67.3 years versus 49% in age > 67.3 years). Within younger patients (age < or = 67.3 years) without remote history of AF, postoperative PAI-1 antigen concentration next determined risk of AF (13% if PAI-1 < or = 28.5 ng/mL versus 46% if PAI-1 > 28.5 ng/mL).
CONCLUSION: An elevated preoperative or postoperative PAI-1 antigen concentration is an independent predictor for development of AF after CPB. Studies are needed to determine whether drugs that reduce PAI-1 concentrations can also reduce the risk of postoperative AF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17846288     DOI: 10.1161/CIRCULATIONAHA.106.677906

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

1.  Obesity and oxidative stress predict AKI after cardiac surgery.

Authors:  Frederic T Billings; Mias Pretorius; Jonathan S Schildcrout; Nathaniel D Mercaldo; John G Byrne; T Alp Ikizler; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

2.  The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades.

Authors:  Jeanne Shen; Shelly Lall; Victoria Zheng; Patricia Buckley; Ralph J Damiano; Richard B Schuessler
Journal:  J Thorac Cardiovasc Surg       Date:  2011-02       Impact factor: 5.209

3.  Transforming growth factor-β in stem cells and tissue homeostasis.

Authors:  Xin Xu; Liwei Zheng; Quan Yuan; Gehua Zhen; Janet L Crane; Xuedong Zhou; Xu Cao
Journal:  Bone Res       Date:  2018-01-31       Impact factor: 13.567

4.  Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Postoperative Atrial Fibrillation.

Authors:  Jordi Heijman; Azinwi Phina Muna; Tina Veleva; Cristina E Molina; Henry Sutanto; Marcel Tekook; Qiongling Wang; Issam H Abu-Taha; Marcel Gorka; Stephan Künzel; Ali El-Armouche; Hermann Reichenspurner; Markus Kamler; Viacheslav Nikolaev; Ursula Ravens; Na Li; Stanley Nattel; Xander H T Wehrens; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-07-30       Impact factor: 17.367

5.  Genetic variation in the β1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery.

Authors:  Janina M Jeff; Brian S Donahue; Kristin Brown-Gentry; Dan M Roden; Dana C Crawford; C Michael Stein; Daniel Kurnik
Journal:  Am Heart J       Date:  2013-10-17       Impact factor: 4.749

Review 6.  Perioperative Biomarkers Predicting Postoperative Atrial Fibrillation Risk After Coronary Artery Bypass Grafting: A Narrative Review.

Authors:  Muhammad S Khan; Kennosuke Yamashita; Vikas Sharma; Ravi Ranjan; Craig H Selzman; Derek J Dosdall
Journal:  J Cardiothorac Vasc Anesth       Date:  2019-09-18       Impact factor: 2.628

7.  Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.

Authors:  Mias Pretorius; Katherine T Murray; Chang Yu; John G Byrne; Frederic T Billings; Michael R Petracek; James P Greelish; Steven J Hoff; Stephen K Ball; Vineet Mishra; Simon C Body; Nancy J Brown
Journal:  Crit Care Med       Date:  2012-10       Impact factor: 7.598

Review 8.  Atrial fibrillation: current knowledge and future directions in epidemiology and genomics.

Authors:  Jared W Magnani; Michiel Rienstra; Honghuang Lin; Moritz F Sinner; Steven A Lubitz; David D McManus; Josée Dupuis; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2011-11-01       Impact factor: 29.690

9.  Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

Authors:  Andreas Goette; Alessandra D'Alessandro; Alicja Bukowska; Siegfried Kropf; Christian Mewis; Christoph Stellbrink; Jürgen Tebbenjohanns; Christian Weiss; Uwe Lendeckel
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

10.  Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation.

Authors:  Dmitry A Zateyshchikov; Alexey N Brovkin; Dimitry A Chistiakov; Valery V Nosikov
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.